Back

Impact of statin and ezetimibe for the prevention of stroke in patients with atrial fibrillation

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Ki Hong Lee

Chonnam National University Hospital, Gwangju (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Use of class ic antiarrhythmic drugs in atrial fibrillation with structural heart disease: a nationwide cohort study
Assistant Professor J. Jeong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
A multicenter analysis of atrial fibrillation burden reduction with antiarrhythmic drugs in patients with cardiac implantable electronic devices
Doctor S. Schwartz (New York, US)
Abstract Slides Video
Presentation thumbnail
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomised controlled trials
Doctor M. Casuso Alvarez (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Improving management of patients with atrial fibrillation in the emergency department based on an aggressive rhythm control strategy. The HEROMEDICUS study.
Doctor N. Argyriou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The contemporary guideline-directed medical therapy (GDMT) for heart failure is associated with a reduced incidence of new-onset atrial fibrillation in the elderly patients
Doctor Y. Mukai (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
The long-term usage of statin prevents adverse events in patients with atrial fibrillation
thumbnail
Congress Presentation
Decreased risk of cardiovascular events in patients with atrial fibrillation treated with lipid-lowering therapy: 2-year follow-up of the Global ETNA-AF program
thumbnail
Congress Presentation
Trimetazidine reduces stroke risk in ischemic atrial fibrillation: a territory-wide, propensity-matched study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources